ESTEATOHEPATITIS ALCOHOLICA PDF

Medwave se preocupa por su privacidad y la seguridad de sus datos personales. Palabras clave: non-alcoholic fatty liver disease, liver steatosis, advanced glycation end products, liver fibrosis, adipocytokines. Se inicia con obesidad y sobrepeso. Figura 1.

Author:Mugis Tesho
Country:Latvia
Language:English (Spanish)
Genre:Art
Published (Last):28 November 2018
Pages:460
PDF File Size:12.52 Mb
ePub File Size:14.85 Mb
ISBN:782-7-31084-644-9
Downloads:38301
Price:Free* [*Free Regsitration Required]
Uploader:Mikanris



Medwave se preocupa por su privacidad y la seguridad de sus datos personales. Palabras clave: non-alcoholic fatty liver disease, liver steatosis, advanced glycation end products, liver fibrosis, adipocytokines. Se inicia con obesidad y sobrepeso. Figura 1. Aun cuando son muchos los tratamientos reportados, los resultados son controversiales.

Algunas de las estrategias reportadas incluyen un cambio de estilo de vida, sensibilizadores de insulina, agentes hipolipemiantes, antioxidantes y citoprotectores [47]. En la Tabla 1 se recapitulan estudios al respecto. Tabla 1. Sanyal y colaboradores [71] , reportaron que la pioglitazona disminuye los valores de aspartato transaminasa y alanina transaminasa. Sin embargo, su uso se limita significativamente debido al incremento de peso [72]. Vitamina E Es un eficaz antioxidante, su uso es reconocido como un tratamiento apropiado para pacientes con esteatohepatitis, sin que cursen por diabetes.

Sin embargo, resultados contrarios fueron reportados por Lavine y colaboradores [64]. Estatinas Son inhibidores competitivos de la hidroximetil coenzima A. Debido a la alta incidencia y prevalencia de obesidad se considera ya una pandemia. Non-alcoholic fatty liver disease refers to a disease spectrum that ranges from steatosis to non-alcoholic steatohepatitis, which leads to fibrosis, cirrhosis and hepatocellular carcinoma.

Given the increasing prevalence of obesity worldwide, the incidence of non-alcoholic fatty liver disease has become a world health problem. Non-alcoholic fatty liver disease is considered to be the hepatic manifestation of metabolic syndrome associated with insulin resistance, central obesity, and type 2 diabetes mellitus.

Allegedly, insulin resistance plays a pivotal role in its pathogenesis. Here we highlight non-alcoholic fatty liver disease epidemiology and pathophysiology, its progression towards steatohepatitis with particular emphasis in liver fibrosis and participation of advanced glycation end products. The different treatments reported are described here as well.

We conducted a search in PubMed with the terms steatohepatitis, steatosis advanced glycation end products, liver fibrosis and adipocytokines.

Articles were selected according to their relevance. Liver steatosis and nonalcoholic steatohepatitis: from pathogenesis to therapy. Medwave Sep;16 8 :e doi: Ficha PubMed. Contacto English Email: Clave:. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.

Aliment Pharmacol Ther. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Esteatosis y esteatohepatitis no alcoholica. The prevalence of nonalcoholic fatty liver disease in the Americas. Ann Hepatol. Dig Dis Sci. Nonalcoholic fatty liver disease diagnosis, pathogenesis and management. Turk J Gastroenterol. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population.

Am J Physiol Endocrinol Metab. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C.

Steatohepatitis: a tale of two "hits"? Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. Nonalcoholic fatty liver disease and atherosclerosis.

Intern Emerg Med. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol. Hepatokines as a Link between Obesity and Cardiovascular Diseases. Diabetes Metab J. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes.

PubMed Matsuzawa Y. Adiponectin: a key player in obesity related disorders. Curr Pharm Des. PubMed Mirza MS. ISRN Gastroenterol. World J Gastroenterol. Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease. World J Hepatol. Leptin receptor signaling: pathways to leptin resistance. Front Biosci Landmark Ed. Evolution of leptin structure and function. Leptin downregulates expression of the gene encoding glucagon in alphaTC cells and mouse islets.

Leptin receptor kDa OB-R protein expression is reduced in obese human skeletal muscle: a potential mechanism of leptin resistance. Exp Physiol. Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol. Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis. Mol Med. Are hepatic steatosis and carotid intima media thickness associated in obese patients with normal or slightly elevated gamma-glutamyl-transferase?

J Transl Med. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha.

J Endocrinol Invest. Adiponectin--it's all about the modifications. Int J Biochem Cell Biol. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab. Liver fibrosis. J Clin Invest. Monitoring fibrogenic progression in the liver. Clin Chim Acta. Pentoxifylline downregulates alpha I collagen expression by the inhibition of Ikappabalpha degradation in liver stellate cells.

Cell Biol Toxicol. J Hepatol. Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical update. Acta Diabetol. Role of the receptor for advanced glycation end products in hepatic fibrosis.

Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol.

ANEMIA PROMIELOCITICA PDF

Statistics

Its pages are open to the members of the Association, as well as to all members of the medical community interested in using this forum to publish their articles in accordance with the journal editorial policies. The principal aim of the journal is to publish original work in the broad field of Gastroenterology, as well as to provide information on the specialty and related areas that is up-to-date and relevant. The scientific works include the areas of Clinical, Endoscopic, Surgical, and Pediatric Gastroenterology, along with related disciplines. The journal accepts original articles, scientific letters, review articles, clinical guidelines, consensuses, editorials, letters to the Editors, brief communications, and clinical images in Gastroenterology in Spanish and English for their publication.

AMAR VERBO INTRANSITIVO MRIO DE ANDRADE EDITORA AGIR PDF

.

Related Articles